-
Myanmar leader lands in Malaysia for migrant return talks
-
Chip industry activists call for South Korea to recognise cancer cases
-
Indian central bank hikes rates for first time since 2023
-
Famine-scarred southern Madagascar braces for El Nino
-
US military on Okinawa face curfew, alcohol ban after murder case
-
How the EU regulates lobbyists
-
Fierce lobbying in EU over 'forever chemicals'
-
I.Coast refuge offers lifelong care for youngsters scorned as 'sorcerers'
-
Dodgers beat Braves and Padres avoid sweep in MLB playoffs
-
Indian central bank hikes rates for first time in more than 3 years
-
Mourning, war and elections as Israel marks October 7
-
Hotel Blacklist Launches New Accommodation Industry Risk Assessment Tool
-
Messi says Argentina retirement is 'saddest day of my career'
-
Bangladesh nuclear plant draws hope -- and worry
-
Oil rises and stocks fall as Hormuz worries flare
-
US beat Canada 1-0 to wrap up four-win international break
-
Pacific presses world for help 'surviving' climate change at pre-COP summit
-
Turkey, Australia's joint COP31 leadership raises doubts
-
Verstappen revival to be put to the test in steamy Singapore
-
For Turkish NGOs, COP31 offers rare space for action
-
US woman who survived botched execution is conscious, speaking: lawyers
-
Sleep, appetite, gene-editing experts contend for Nobel chemistry prize
-
Climate champion Australia digging more coal
-
Nobel Peace Prize haunted by the 'spectre' of Trump
-
Emotion, tears as Messi retires from Argentina national team
-
Africa launches own credit agency in bid for cheaper borrowing
-
Dodgers push Braves to the brink of MLB playoff exit
-
US, China, EU: three paths to regulating AI
-
Crisis-stricken Haiti postpones elections
-
Australia's High Court rules against coal mine in landmark climate case
-
N. Korea's Kim pledges 'invariable support' in Putin birthday letter
-
Australia touts new funds for Pacific infrastructure at Fiji 'pre-COP'
-
OGRD Alliance Advances PLPC Multi-Asset Platform Following APHELAR Milestone, Expanding Licensing and Strategic Capital Frameworks
-
Eva Marie Saint, Oscar winner of Hollywood classics, dies at 102
-
Emotion, tears as Messi prepares for Argentina farewell
-
Australia probes app used in cheap smart glasses over privacy fears
-
Kane eyes Ronaldo record after matching England cap mark
-
England needed to 'move on' from World Cup pain, says Tuchel
-
Spain fight back to beat Croatia, Kane adds to record for England
-
O'Neill to stay at Celtic after period of "reflection"
-
Merino double helps Spain beat Croatia, reach Nations League quarters
-
Kane marks 125th England cap with Wembley Nations League double
-
US stocks hit fresh records as oil stabilizes on rising supplies
-
Quebec's incoming separatist leader wants to block Crown from swearing-in
-
As Messi bows out, Argentines say 'thank you'
-
Emmys gala will now stream its premier television awards
-
Ronaldo opens door for Portugal return, apologises for walkout
-
Paramount completes Warner Bros takeover, creating Skydance
-
'Nobody seems to care': Russian city shrugs off plague reports
-
Trump blames France unrest on Islam, migration
Trump 'considering' push to reclassify marijuana as less dangerous
US President Donald Trump on Monday said his administration could push to loosen federal restrictions on marijuana, reclassifying it as a less dangerous drug.
"We are considering that," Trump told reporters after he was queried whether an executive order on the issue was being discussed.
"A lot of people want to see it, the reclassification, because it leads to tremendous amounts of research that can't be done unless you reclassify, so we are looking at that very strongly."
At the federal level, marijuana is currently classified as a Schedule I substance, in the same league as drugs like heroin and LSD. The government considers these drugs to have high abuse potential without accepted use for medical treatment.
But dozens of US states already have legal medical marijuana programs, and many also have approved its recreational use.
According to a recent Washington Post report, Trump is aiming to push for a reclassification to Schedule III -- substances that are considered to have medical value and less potential for abuse.
That class includes ketamine and anabolic steroids.
Rescheduling is not legalization or decriminalization -- but easing federal restrictions could have ripple effects, including lowering barriers to pursue research, as authorizing clinical studies on Schedule I substances can require many layers of approval.
It could also have major tax implications for companies that legally grow and sell cannabis.
The US president cannot unilaterally reclassify a drug. The Post reported that Trump is expected to sign an executive order directing federal agencies to pursue reclassification.
Joe Biden's administration had previously pursued reclassification, but efforts stalled and were not completed before Trump took office in early 2025.
The US has a patchwork of state-level regulations regarding the commercial distribution, recreational possession and personal cultivation of cannabis.
In small amounts it is already legal for recreational use in 24 US states as well as Washington DC.
M.AlAhmad--SF-PST